Invivyd, Inc. Common Stock (IVVD) Stock
Key stats
- Market cap
- $176.65M
- Price / Earnings ratio
- -1.6x
- EPS (TTM)
- -$0.33
- Volume
- Loading
- 52-week high
- $3.07
- 52-week low
- $0.53
Source: third-party data provider, as of November 13, 2026
Compare with IVVD
Recent news

Invivyd's VYD2311 Phase III Study Meets Safety Goals, Eyes FDA Accelerated Approval
Invivyd's VYD2311 Phase III Study Meets Safety Goals, Eyes FDA Accelerated Approval
IVVD

3 Small-Cap Biotechs With Binary Catalysts on the Calendar
3 Small-Cap Biotechs With Binary Catalysts on the Calendar
IVVD

Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates
Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates
IVVD

IVVD Stock Drops As PEMGARDA Loses Emergency Authorization In 2027 — Invivyd Eyes Full FDA Approval
IVVD Stock Drops As PEMGARDA Loses Emergency Authorization In 2027 — Invivyd Eyes Full FDA Approval
IVVD
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 44.19
- MACD 12/26/9
- -0.04
- EMA 9 of MACD
- -0.05
- MACD histogram
- 0.01
- SMA 50
- $0.73
- Price below SMA 50
- EMA 50
- $0.70
- Price below EMA 50
- SMA 200
- $1.10
- Price below SMA 200
- EMA 200
- $1.20
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Invivyd's VYD2311 Phase III Study Meets Safety Goals, Eyes FDA Accelerated Approval
Invivyd's VYD2311 Phase III Study Meets Safety Goals, Eyes FDA Accelerated Approval
IVVD

3 Small-Cap Biotechs With Binary Catalysts on the Calendar
3 Small-Cap Biotechs With Binary Catalysts on the Calendar
IVVD

Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates
Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates
IVVD

IVVD Stock Drops As PEMGARDA Loses Emergency Authorization In 2027 — Invivyd Eyes Full FDA Approval
IVVD Stock Drops As PEMGARDA Loses Emergency Authorization In 2027 — Invivyd Eyes Full FDA Approval
IVVD

Invivyd doses first participants in Phase 3 COVID-19 trial
Invivyd doses first participants in Phase 3 COVID-19 trial
IVVD

IVVD Stock Tanks 19% Today – But This Analyst Believes It Has A Potential Upside Of Over 730%
IVVD Stock Tanks 19% Today – But This Analyst Believes It Has A Potential Upside Of Over 730%
IVVD

Invivyd Q1 Earnings Call Highlights
Invivyd Q1 Earnings Call Highlights
IVVD

Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates
Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates
IVVD

5 Stocks That More Than Doubled Halfway Through Q1
5 Stocks That More Than Doubled Halfway Through Q1
IVVD

3 Groundbreaking Biotech Stocks to Invest in Now
3 Groundbreaking Biotech Stocks to Invest in Now
IVVD
News tone: automated (AI) classification of the article's content, not a price prediction.
About Invivyd, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Marc William Elia | CEO & Chairperson of the Board | 1976 |
| Mr. William E. Duke Jr., M.B.A. | CFO and Principal Financial & Accounting Officer | 1972 |
| Ms. Jill Andersen J.D. | Chief Legal Officer & Corporate Secretary | 1973 |
| Mr. Timothy Lee | Chief Commercial Officer | 1974 |
| Dr. Robert D. Allen Ph.D. | Chief Scientific Officer | 1970 |
| Ms. Kristie Coneys Kuhl J.D. | Chief Communications Officer | — |
| Ms. Julie Green M.B.A. | Chief Human Resources Officer | 1976 |
| Ms. Rachael Gerlach Ph.D. | Senior Vice President of Regulatory Affairs | — |
| Ms. Katie Falzone CPA | Senior Vice President of Finance | — |
| Dr. Michael J. Mina M.D., Ph.D. | Chief Medical Officer & Chief Epidemiologist | 1984 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 44.19
- MACD 12/26/9
- -0.04
- EMA 9 of MACD
- -0.05
- MACD histogram
- 0.01
- SMA 50
- $0.73
- Price below SMA 50
- EMA 50
- $0.70
- Price below EMA 50
- SMA 200
- $1.10
- Price below SMA 200
- EMA 200
- $1.20
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $10.00
- Average
- $10.00
- High
- $10.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022 | -35.2 | +21.9 | -44.2 | -32.1 | ||||||||
| 2023 | +47.1 | -23.0 | -30.6 | -3.5 | +45.2 | -30.0 | +25.4 | +28.3 | -7.1 | -4.8 | +4.1 | +155.8 |
| 2024 | +30.7 | -18.1 | +9.1 | -47.8 | -24.0 | -39.2 | +4.2 | -29.2 | +20.0 | -1.1 | -23.1 | -37.1 |
| 2025 | -25.0 | +9.4 | -35.1 | +16.7 | +54.1 | -22.6 | -4.2 | +32.9 | +6.8 | +44.3 | +50.9 | -1.2 |
| 2026 | -30.4 | -2.9 | -24.4 | +5.3 | -25.0 | -28.7 | -36.5 | +72.7 | -1.1 | -29.3 | +3.4 |



